<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **PROSD-3**  
External requests from Exosome Diagnostics, Inc requesting inclusion of ExosomeDx Prostate IntelliScore (EPI) non-DRE urine test in patients with PSA levels between 2-10ng/mL who have not yet had a biopsy.  
Specifically: Revise footnote “i” to include EPI as suggested in bold. “Biomarkers that improve the specificity of detection are not, as yet, recommended as first line screening tests. However, there may be some patients who meet PSA standards for consideration of prostate biopsy, but for whom the patient and/or the physician wish to further define the probability of high-grade cancer. A percent-free PSA <10%, PHI >35, **EPI score greater than 15.6** or 4Kscore (which provides an estimate of the probability of high-grade prostate cancer) are potentially informative in patients who have never undergone biopsy or after a negative biopsy; a PCA3 score >35 is potentially informative after a negative biopsy.” | Based on the data in the noted references and discussion the panel consensus was to revise the noted footnote for patients with indications for biopsy (PSA >3 ng/mL for ages 45-75y, PSA ≥ 4 ng/mL for ages >75y, and/or very suspicious DRE) and include EPI as suggested.  
See submission for references. | YES | NO | ABSTAIN | ABSENT |
| **PROSD-3**  
External requests from MDxHealth requesting inclusion of the SelectMDx test within the evaluation of and indications for biopsy. | Based on a review of data and discussion, the panel consensus did not support the addition of these specific recommendations into the Guidelines [due to insufficient available data]. | 0 | 16 | 0 | 11 |
See submission for references.